多巴胺受体激动剂对帕金森病睡眠障碍影响的研究进展
|
摘要
睡眠障碍是帕金森病(PD)最常见的非运动症状之一,对患者生活质量有显著的负面影响。非麦角类多巴胺受体激动剂(如罗匹尼罗,普拉克索,罗替戈汀和阿扑吗啡,等)可以缓解PD患者的一些睡眠障碍问题,但另一些睡眠障碍问题则有可能会被诱发。虽然,PD患者的睡眠障碍与普通人群中的睡眠障碍有着大多数的共同特征,然而对于PD患者群体来说,治疗睡眠障碍应有一些特殊考虑。文中就多巴胺受体激动剂改善和诱发PD患者睡眠障碍的研究进展做综述。
Sleep disorders are one of the most common non-exercise manifestations of Parkinson's disease( PD) and have a significant negative impact on quality of life. Non-ergoline dopamine receptor agonists,such as ropinirole,pramipexole,rotigotine and apomorphine,can alleviate some sleep disorders in PD patients,while other sleep disorders may be induced. Although the sleep disorder of PD has most of the common features of sleep disorders in the general population,there are some special considerations for the treatment in this patient population. How dopamine agonists improve and induce sleep disorders in PD patients was discussed.
Sleep disorders are one of the most common non-exercise manifestations of Parkinson's disease( PD) and have a significant negative impact on quality of life. Non-ergoline dopamine receptor agonists,such as ropinirole,pramipexole,rotigotine and apomorphine,can alleviate some sleep disorders in PD patients,while other sleep disorders may be induced. Although the sleep disorder of PD has most of the common features of sleep disorders in the general population,there are some special considerations for the treatment in this patient population. How dopamine agonists improve and induce sleep disorders in PD patients was discussed.
引文
[1] Amara AW, Chahine LM, Videnovic A. Treatment of Sleep Dysfunction in Parkinson's Disease[J]. Curr Treat Options Neurol, 2017, 19:26
[2] Albers JA, Chand P, Anch AM. Multifactorial sleep disturbance in Parkinson's disease[J]. Sleep Med, 2017, 35:41-48
[3] Falup-Pecurariu C, Diaconu. Sleep Dysfunction in Parkinson's Disease[J]. Int Rev Neurobiol, 2017, 133:719-742
[4] American Academy of Sleep Medicine. International Classifcation of Sleep Disorders[M]. 3rd ed. Darien, IL:American Academy of Sleep Medicine, 2014
[5] Loddo G, Calandra-Buonaura G, Sambati L, et al. The Treatment of Sleep Disorders in Parkinson's Disease:From Research to Clinical Practice[J]. Front Neurol, 2017, 8:42
[6] Pignatelli M, Bonci A. Role of Dopamine Neurons in Reward and Aversion:A Synaptic Plasticity Perspective[J]. Neuron,2015, 86:1145-1157
[7] Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update:Treatments for the non-motor symptoms of Parkinson's disease[J]. Mov Disord, 2011,26 Suppl 3:S42-80
[8] Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al.Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease[J]. Eur J Neurol, 2012,19:105-113
[9] Moccia M, Erro R, Picillo M, et al. A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease[J].Sleep, 2016, 39:405-412
[10]Auffret M, Drapier S, Vérin M. The Many Faces of Apomorphine:Lessons from the Past and Challenges for the Future[J]. Drugs R D, 2018,18:91-107
[11]Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease:a double-blind, randomized, placebo-controlled study(RECOVER)[J]. Mov Disord, 2011, 26:90-99
[12]Calandra-Buonaura G, Guaraldi P, Doria A, et al. Rotigotine Objectively Improves Sleep in Parkinson's Disease:An OpenLabel Pilot Study with Actigraphic Recording[J]. Parkinsons Dis, 2016,2016:3724148
[13]Pierantozzi M, Placidi F, Liguori C, et al. Rotigotine may improve sleep architecture in Parkinson's disease:a doubleblind, randomized, placebo-controlled polysomnographic study[J]. Sleep Med, 2016, 21:140-144
[14]Pagonabarraga J, Piol G, Cardozo A, et al. Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease:Results of the Multicenter, Prospective SLEEP-FRAM Study[J].Parkinsons Dis, 2015,2015:131508
[15]Giladi N, Fichtner A, Poewe W, et al. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease[J]. J Neural Transm(Vienna), 2010, 117:1395-1399
[16]Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease:a double-blind, double-dummy, randomised controlled trial[J].Lancet Neurol, 2007,6:513-520
[17]Mller JC, Oertel WH, Kster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease:results from a European multicenter trial[J]. Mov Disord, 2005, 20:602-610
[18]Wishart S, Macphee GJ. Evaluation and management of the nonmotor features of Parkinson's disease[J]. Ther Adv Chronic Dis,2011, 2:69-85
[19]Zoetmulder M, Nikolic M, Biernat H, et al. Increased Motor Activity During REM Sleep Is Linked with Dopamine Function in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease[J]. J Clin Sleep Med, 2016,12:895-903
[20]Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder(RBD)[J]. J Clin Sleep Med, 2010, 6:85-95
[21]Wailke S, Herzog J, Witt K, et al. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease[J]. Eur J Neurol, 2011,18:590-596
[22]Kleiner-Fisman G, Stern MB, Fisman DN. Health-related quality of life in Parkinson disease:correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale(UPDRS)in U. S. male veterans[J]. Health Qual Life Outcomes, 2010,8:91
[23]Müller T, Marg M, Rothe H, et al. Continuous Subcutaneous Apomorphine Infusion Improves Severe Restless Legs Syndrome[J]. Mov Disord Clin Pract, 2014, 1:233-234
[24]Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease:a double-blind, randomized, placebo-controlled study(RECOVER)[J]. Mov Disord, 2011, 26:90-99
[25]Baumann CR, Marti I, Bassetti CL. Restless legs symptoms without periodic limb movements in sleep and without response to dopaminergic agents:a restless legs-like syndrome?[J]. Eur J Neurol, 2007,14:1369-1372
[26]Szatmari S Jr, Bereczki D, Fornadi K, et al. Association of Restless Legs Syndrome With Incident Parkinson's Disease[J].Sleep, 2017,40(2)
[27]Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome[J]. Neurotherapeutics, 2012, 9:776-790
[28]Knie B, Mitra MT, Logishetty K, et al. Excessive daytime sleepiness in patients with Parkinson's disease[J]. CNS Drugs,2011, 25:203-212
[29]Shen Y, Huang JY, Li J, et al. Excessive Daytime Sleepiness in Parkinson's Disease:Clinical Implications and Management[J].Chin Med J(Engl), 2018, 131:974-981
[30]Hauser RA, Gauger L, Anderson WM, et al. Pramipexoleinduced somnolence and episodes of daytime sleep[J]. Mov Disord, 2000, 15:658-663
[31]Brusa L, Musco S, Bernardi G, et al. Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients[J]. Parkinsonism Relat Disord, 2014, 20:931-932
[32]Herer B, Arnulf I, Housset B. Effects of levodopa on pulmonary function in Parkinson's disease[J]. Chest, 2001, 119:387-393
[33]Valko PO, Hauser S, Sommerauer M, et al. Observations on sleep-disordered breathing in idiopathic Parkinson's disease[J].PLo S One, 2014, 9:e100828
[34]Gros P, Mery VP, Lafontaine AL, et al. Obstructive sleep apnea in Parkinson's disease patients:effect of Sinemet CR taken at bedtime[J]. Sleep Breath, 2016, 20:205-212
[35]De Cock VC, Vidailhet M, Arnulf I. Sleep disturbances in patients with parkinsonism[J]. Nat Clin Pract Neurol, 2008,4:254-266
[36]Auffret M, Drapier S, Vérin M. The Many Faces of Apomorphine:Lessons from the Past and Challenges for the Future[J]. Drugs R D, 2018, 18:91-107
[37]Uchiyama T, Sakakibara R, Yoshiyama M, et al. Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats[J]. Neuroscience, 2009, 162:1333-1338
[2] Albers JA, Chand P, Anch AM. Multifactorial sleep disturbance in Parkinson's disease[J]. Sleep Med, 2017, 35:41-48
[3] Falup-Pecurariu C, Diaconu. Sleep Dysfunction in Parkinson's Disease[J]. Int Rev Neurobiol, 2017, 133:719-742
[4] American Academy of Sleep Medicine. International Classifcation of Sleep Disorders[M]. 3rd ed. Darien, IL:American Academy of Sleep Medicine, 2014
[5] Loddo G, Calandra-Buonaura G, Sambati L, et al. The Treatment of Sleep Disorders in Parkinson's Disease:From Research to Clinical Practice[J]. Front Neurol, 2017, 8:42
[6] Pignatelli M, Bonci A. Role of Dopamine Neurons in Reward and Aversion:A Synaptic Plasticity Perspective[J]. Neuron,2015, 86:1145-1157
[7] Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update:Treatments for the non-motor symptoms of Parkinson's disease[J]. Mov Disord, 2011,26 Suppl 3:S42-80
[8] Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al.Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease[J]. Eur J Neurol, 2012,19:105-113
[9] Moccia M, Erro R, Picillo M, et al. A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease[J].Sleep, 2016, 39:405-412
[10]Auffret M, Drapier S, Vérin M. The Many Faces of Apomorphine:Lessons from the Past and Challenges for the Future[J]. Drugs R D, 2018,18:91-107
[11]Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease:a double-blind, randomized, placebo-controlled study(RECOVER)[J]. Mov Disord, 2011, 26:90-99
[12]Calandra-Buonaura G, Guaraldi P, Doria A, et al. Rotigotine Objectively Improves Sleep in Parkinson's Disease:An OpenLabel Pilot Study with Actigraphic Recording[J]. Parkinsons Dis, 2016,2016:3724148
[13]Pierantozzi M, Placidi F, Liguori C, et al. Rotigotine may improve sleep architecture in Parkinson's disease:a doubleblind, randomized, placebo-controlled polysomnographic study[J]. Sleep Med, 2016, 21:140-144
[14]Pagonabarraga J, Piol G, Cardozo A, et al. Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease:Results of the Multicenter, Prospective SLEEP-FRAM Study[J].Parkinsons Dis, 2015,2015:131508
[15]Giladi N, Fichtner A, Poewe W, et al. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease[J]. J Neural Transm(Vienna), 2010, 117:1395-1399
[16]Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease:a double-blind, double-dummy, randomised controlled trial[J].Lancet Neurol, 2007,6:513-520
[17]Mller JC, Oertel WH, Kster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease:results from a European multicenter trial[J]. Mov Disord, 2005, 20:602-610
[18]Wishart S, Macphee GJ. Evaluation and management of the nonmotor features of Parkinson's disease[J]. Ther Adv Chronic Dis,2011, 2:69-85
[19]Zoetmulder M, Nikolic M, Biernat H, et al. Increased Motor Activity During REM Sleep Is Linked with Dopamine Function in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease[J]. J Clin Sleep Med, 2016,12:895-903
[20]Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder(RBD)[J]. J Clin Sleep Med, 2010, 6:85-95
[21]Wailke S, Herzog J, Witt K, et al. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease[J]. Eur J Neurol, 2011,18:590-596
[22]Kleiner-Fisman G, Stern MB, Fisman DN. Health-related quality of life in Parkinson disease:correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale(UPDRS)in U. S. male veterans[J]. Health Qual Life Outcomes, 2010,8:91
[23]Müller T, Marg M, Rothe H, et al. Continuous Subcutaneous Apomorphine Infusion Improves Severe Restless Legs Syndrome[J]. Mov Disord Clin Pract, 2014, 1:233-234
[24]Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease:a double-blind, randomized, placebo-controlled study(RECOVER)[J]. Mov Disord, 2011, 26:90-99
[25]Baumann CR, Marti I, Bassetti CL. Restless legs symptoms without periodic limb movements in sleep and without response to dopaminergic agents:a restless legs-like syndrome?[J]. Eur J Neurol, 2007,14:1369-1372
[26]Szatmari S Jr, Bereczki D, Fornadi K, et al. Association of Restless Legs Syndrome With Incident Parkinson's Disease[J].Sleep, 2017,40(2)
[27]Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome[J]. Neurotherapeutics, 2012, 9:776-790
[28]Knie B, Mitra MT, Logishetty K, et al. Excessive daytime sleepiness in patients with Parkinson's disease[J]. CNS Drugs,2011, 25:203-212
[29]Shen Y, Huang JY, Li J, et al. Excessive Daytime Sleepiness in Parkinson's Disease:Clinical Implications and Management[J].Chin Med J(Engl), 2018, 131:974-981
[30]Hauser RA, Gauger L, Anderson WM, et al. Pramipexoleinduced somnolence and episodes of daytime sleep[J]. Mov Disord, 2000, 15:658-663
[31]Brusa L, Musco S, Bernardi G, et al. Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients[J]. Parkinsonism Relat Disord, 2014, 20:931-932
[32]Herer B, Arnulf I, Housset B. Effects of levodopa on pulmonary function in Parkinson's disease[J]. Chest, 2001, 119:387-393
[33]Valko PO, Hauser S, Sommerauer M, et al. Observations on sleep-disordered breathing in idiopathic Parkinson's disease[J].PLo S One, 2014, 9:e100828
[34]Gros P, Mery VP, Lafontaine AL, et al. Obstructive sleep apnea in Parkinson's disease patients:effect of Sinemet CR taken at bedtime[J]. Sleep Breath, 2016, 20:205-212
[35]De Cock VC, Vidailhet M, Arnulf I. Sleep disturbances in patients with parkinsonism[J]. Nat Clin Pract Neurol, 2008,4:254-266
[36]Auffret M, Drapier S, Vérin M. The Many Faces of Apomorphine:Lessons from the Past and Challenges for the Future[J]. Drugs R D, 2018, 18:91-107
[37]Uchiyama T, Sakakibara R, Yoshiyama M, et al. Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats[J]. Neuroscience, 2009, 162:1333-1338